On Apr. 14, 1993, the Earl Davie/ZymoGenetics Endowed Chair of Biochemistry at the University of Washington was established with a $2 million gift to the UW by ZymoGenetics and its parent company Novo Nordisk of Denmark.

The first chair created by a biotechnology company recognizes Davie’s breakthroughs in discovering and genetically engineering blood clotting factors.